학술논문
Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
Document Type
Article
Author
Mehra, Niven; Antonarakis, Emmanuel S.; Park, Se Hoon; Goh, Jeffrey C.; McDermott, Raymond S.; Sala González, Nuria; Fong, Peter C.C.; Greil, Richard; De Santis, Maria; Yanez, Patricio Eduardo; Huang, Yi-Hsiu; Begbie, Stephen; Rey, Felipe; Kramer, Gero; Suzuki, Hiroyoshi; Saretsky, Todd L.; Ghate, Sameer R.; Cui, Yi; Kim, Jeri; Yu, Evan Y.
Source
Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, p131-131, 1p
Subject
Language
ISSN
0732183X